+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Overactive Bladder - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762897
  • Report
  • April 2019
  • Region: Global
  • 89 pages
  • VPA Research
1 of 3


  • Aetas Pharma Co Ltd
  • Astellas Pharma Inc
  • Dong-A ST Co Ltd
  • FemPulse Corporation
  • Medy-Tox Inc
  • Mylan NV
  • MORE

Overactive Bladder pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Overactive Bladder R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Overactive Bladder report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Overactive Bladder as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Overactive Bladder with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Overactive Bladder pipeline Profiled in detail

Key players actively participating in Overactive Bladder pipeline are profiled along with their R&D progress in Overactive Bladder treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Overactive Bladder pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Overactive Bladder treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Overactive Bladder pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Overactive Bladder pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Overactive Bladder pipeline study
  • All recent news and developments related to Overactive Bladder drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • Aetas Pharma Co Ltd
  • Astellas Pharma Inc
  • Dong-A ST Co Ltd
  • FemPulse Corporation
  • Medy-Tox Inc
  • Mylan NV
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Overactive Bladder Disease Overview

3. Overactive Bladder R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Overactive Bladder Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Overactive Bladder Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Overactive Bladder companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Overactive Bladder Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Aetas Pharma Co Ltd
  • Allergan Plc
  • Astellas Pharma Inc
  • Dare Bioscience Inc
  • Dong-A ST Co Ltd
  • Evestra Inc
  • FemmePharma Global Healthcare Inc
  • FemPulse Corporation
  • Ipsen SA
  • Kissei Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Medy-Tox Inc
  • Mezzion Pharma Co Ltd
  • Mylan NV
  • Outpost Medicine Ltd
  • Recordati SpA
  • Taiho Pharmaceutical Co Ltd
  • Taris Biomedical LLC
  • TheraVida Inc
  • Urovant Sciences GmbH
  • Velicept Therapeutics Inc
Note: Product cover images may vary from those shown